{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:35Z","timestamp":1793412155238,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arabia, followed by genotype 1. The HCV genotype affects the response to different HCV treatments and the progression of liver disease. Currently, combinations of direct-acting antiviral drugs (DAAs) approved for the treatment of HCV achieve high cure rates with minimal adverse effects. Because real-world data from Saudi Arabia about the efficacy of DAAs are still limited, this study was conducted to assess the effectiveness of DAAs in treating patients with chronic hepatitis C and to identify the variables related to a sustained virologic response (SVR) in a real-world setting in Saudi Arabia. This prospective cohort study included 200 Saudi patients with chronic HCV who were 18 years of age or older and had been treated with DAAs at King Abdul-Aziz Specialized Hospital in Taif, Saudi Arabia, between September 2018 and March 2021. The response to treatment was assessed by whether or not an SVR had been achieved at week 12 post treatment (SVR12). An SVR12 was reached in 97.5% of patients. SVR12 rates were comparable for patients of different ages, between men and women, and between patients with and without cirrhosis. In addition, the SVR12 rates did not differ according to the infecting HCV genotype. In this study, the presence of cirrhosis and the patient\u2019s gender were independent predictors of who would not reach an SVR12 (known here as the non-SVR12 group) according to the results of univariate and multivariate binary logistic regression analyses based on the determinants of SVR12. In this population of patients with chronic HCV infection, all DAA regimens achieved very high SVR12 rates. The patients\u2019 gender and the presence of cirrhosis were independent factors of a poor response.<\/jats:p>","DOI":"10.3390\/tropicalmed8020092","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T11:19:53Z","timestamp":1675077593000},"page":"92","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital"],"prefix":"10.3390","volume":"8","author":[{"given":"Nahed Mohammed","family":"Hawsawi","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-2184","authenticated-orcid":false,"given":"Tamer","family":"Saber","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein M.","family":"Salama","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-5027","authenticated-orcid":false,"given":"Walaa S.","family":"Fouad","sequence":"additional","affiliation":[{"name":"Departments of Family Medicine, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howaida M.","family":"Hagag","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"},{"name":"Department of Pathology, Faculty of Medicine, Al-Azhar University, Cairo 11884, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-081X","authenticated-orcid":false,"given":"Hayaa M.","family":"Alhuthali","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad M.","family":"Eed","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"},{"name":"Medical Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Shebinel Kom 32511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisir","family":"Saber","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"},{"name":"Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-7806","authenticated-orcid":false,"given":"Khadiga A.","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"},{"name":"Department of Parasitology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham H.","family":"Al Qurashi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, King Abdul-Aziz Specialized Hospital, Taif 26521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Altowairqi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, King Abdul-Aziz Specialized Hospital, Taif 26521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohmmad","family":"Samaha","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Department, King Abdul-Aziz Specialized Hospital, Taif 26521, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"El-Hossary","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijid.2016.03.012","article-title":"Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence","volume":"46","author":"Mohamoud","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: Welcoming advances in evaluation and management","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","article-title":"Hepatitis C virus and the kidney","volume":"15","author":"Pol","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Jefferies","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"ref_5","unstructured":"WHO (2021, September 10). Global Hepatitis Report 2021, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3855\/jidc.7880","article-title":"Prevalence and predictors of hepatitis B in Jeddah City, Saudi Arabia: A population-based seroprevalence study","volume":"10","author":"Dashash","year":"2016","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/sjg.SJG_421_18","article-title":"Hepatitis B care pathway in Saudi Arabia: Current situation, gaps and actions","volume":"25","author":"Sanai","year":"2019","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_8","unstructured":"World Health Organization (2021, September 10). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Towards Ending Viral Hepatitis, Available online: http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/omi.1.2000.5.129","article-title":"Genome of human hepatitis C virus (HCV): Gene organization, sequence diversity, and variation","volume":"5","author":"Kato","year":"2000","journal-title":"Microb. Comp. Genom."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.391","article-title":"Topology of hepatitis C virus envelope glycopro-teins","volume":"13","author":"Dubuisson","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals fora unified system of nomenclature of hepatitis C virusgenotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tsukiyama-Kohara, K., and Kohara, M. (2017). Hepatitis C virus: Viralquasispecies and genotypes. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010023"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: The role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Abdelhameed, R.F.A., Ibrahim, A.K., Elfaky, M.A., Habib, E.S., Mahamed, M.I., Mehanna, E.T., Darwish, K.M., Khodeer, D.M., Ahmed, S.A., and Elhady, S.S. (2021). Antioxidant and Anti-Inflammatory Activity of Cynanchum Acutum L. Isolated Flavonoids Using Experimentally Induced Type 2 Diabetes Mellitus: Biological and In Silico Investigation for NF-\u039aB Pathway\/MiR-146a Expression Modulation. Antioxidants, 10.","DOI":"10.3390\/antiox10111713"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Globalepidemiology of hepatitis C virus infection: An up-date of thedistribution and circulation of hepatitis C virus genotypes","volume":"22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence andgenotype distribution of hepatitis C virus infection in 2015, amodelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12985-017-0873-7","article-title":"Hepatitis C virus genotypes in Saudi Arabia: A future prediction and laboratory profile","volume":"14","author":"Bawazir","year":"2017","journal-title":"Virol. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/kjm2.12317","article-title":"Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study","volume":"37","author":"Yu","year":"2020","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bjid.2020.06.010","article-title":"Hepatitis C virus genotypes and associated risk factors in the state of Par\u00e1, Northern Brazil","volume":"24","author":"Amoras","year":"2020","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1038\/s41598-020-60128-w","article-title":"The Effects of Sildenafil and\/or Nitroglycerin on Random-Pattern Skin Flaps After Nicotine Application in Rats","volume":"10","author":"Ellabban","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_23","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 clinical practice guidelines on the management of hepatitis C virus infection. J. Hepatol., 66, 153\u2013194."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4254\/wjh.v7.i3.616","article-title":"Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease","volume":"7","author":"Shaheen","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4254\/wjh.v8.i2.92","article-title":"Chronic hepatitis C: This and the new era of treatment","volume":"8","author":"Bertino","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jmii.2018.09.005","article-title":"Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data","volume":"53","author":"Hong","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7150\/ijms.43079","article-title":"Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges","volume":"17","author":"Zeng","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/HMER.S190967","article-title":"Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain","volume":"11","author":"Abdulla","year":"2019","journal-title":"Hepat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1949797","DOI":"10.1080\/19932820.2021.1949797","article-title":"Effectiveness of direct-acting antiviral drugs against hepatitis C virus: Predictive factors of response to the treatment","volume":"16","year":"2021","journal-title":"Libyan J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Chung","year":"2015","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.4103\/1319-3767.188067","article-title":"SASLT guidelines: Update in treatment of Hepatitis C virus infection","volume":"22","author":"Alghamdi","year":"2016","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14218\/JCTH.2017.00067","article-title":"Hepatitis C virus and hepatocellular carcinoma: A narrative review","volume":"6","author":"Axley","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_34","first-page":"214","article-title":"Hepatitis C virus and liver transplantation","volume":"13","author":"Bhamidimarri","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/1319-3767.187609","article-title":"Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift","volume":"22","author":"Aljumah","year":"2016","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1871526517666170417143216","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon- alfa interferon in treatment of a cohort of Egyptian patients with hepatitis C virus infection","volume":"17","author":"Ahmed","year":"2017","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11136-019-02111-1","article-title":"Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: A comparison with the general population","volume":"28","author":"Juanbeltz","year":"2019","journal-title":"Qual. Life Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Abdel-Moneim, A., Bamaga, M., Shehab, G., Abu Elsaad, A., and Farahat, F. (2012). HCV Infection among Saudi Population: High Prevalence of Genotype 4 and Increased Viral Clearance Rate. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029781"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jsps.2022.07.005","article-title":"The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia","volume":"30","author":"Alarfaj","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_40","first-page":"e40357","article-title":"The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis","volume":"16","author":"Sharafi","year":"2016","journal-title":"Hepat. Mon."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/AZMJ.AZMJ_76_18","article-title":"Efficacy and safety of daclatasvir-containing regimens in the treatment of chronic hepatitis C patients in Damietta","volume":"18","author":"Hashim","year":"2020","journal-title":"Al-Azhar Assiut Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/IDR.S153060","article-title":"Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection","volume":"11","author":"Ahmed","year":"2018","journal-title":"Drug Resist. Infect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jmv.25478","article-title":"High success rates for the use of ombitasvir\/paritaprevir\/ritonavir containing regimens in treatment of na\u00efve and experienced chronic hepatitis C genotype 4: Real world results","volume":"94","author":"Alboraie","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.3748\/wjg.v25.i44.6551","article-title":"Real-life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China","volume":"25","author":"Yang","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/gastroent12030031","article-title":"Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients","volume":"12","author":"Kamel","year":"2021","journal-title":"Gastroenterol. Insights"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Iliescu, E.L., Mercan-Stanciu, A., and Toma, L. (2020). Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-1687-1"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1590\/1806-9282.65.12.1470","article-title":"Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: A clinical experience","volume":"65","author":"Tatar","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jmv.25033","article-title":"Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real-world study","volume":"90","author":"Marciano","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00705-017-3573-0","article-title":"Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice","volume":"163","author":"Soliman","year":"2018","journal-title":"Arch. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","article-title":"Management of direct-acting antiviral agent failures","volume":"63","author":"Buti","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/MEG.0000000000001672","article-title":"Elastography and serum markers of fbrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C","volume":"32","author":"Abdelsameea","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2019.01.011","article-title":"Visual and brainstem auditory evoked potentials in HCV-infected patients before and after interferon-free therapy\u2014A pilot study","volume":"80","author":"Bladowskab","year":"2019","journal-title":"Int. J. Infect. Dis."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/8\/2\/92\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:19:42Z","timestamp":1760120382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/8\/2\/92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["tropicalmed8020092"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed8020092","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]}}}